Lifesci Capital Issues Optimistic Estimate for PVLA Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Research analysts at Lifesci Capital raised their FY2026 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a note issued to investors on Tuesday, February 24th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($4.55) per share for the year, up from their previous forecast of ($4.72). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

PVLA has been the subject of several other reports. Raymond James Financial reissued a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Oppenheimer reissued an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. Craig Hallum initiated coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. Chardan Capital increased their target price on shares of Palvella Therapeutics from $174.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group lifted their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $176.44.

Palvella Therapeutics Stock Up 15.3%

Shares of NASDAQ PVLA opened at $148.34 on Thursday. The business’s 50 day moving average is $93.82 and its two-hundred day moving average is $79.34. The company has a market cap of $1.76 billion, a P/E ratio of -56.40 and a beta of -0.16. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in Palvella Therapeutics during the 1st quarter worth $7,553,000. Goldman Sachs Group Inc. acquired a new position in shares of Palvella Therapeutics in the first quarter valued at about $533,000. Geode Capital Management LLC grew its stake in shares of Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the second quarter worth about $37,000. Finally, JPMorgan Chase & Co. raised its stake in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 20.50% of the company’s stock.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 / late‑stage clinical news has driven investor enthusiasm — coverage and headlines about a late‑stage win for Palvella’s lead asset are cited as a major momentum driver. Palvella Therapeutics shares surge on positive Phase 3 trial results
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and bumped its price target to $255 (from $200), and the firm retains a Buy — analyst upgrades and a hawkish target boost sentiment and institutional interest. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
• Positive Sentiment: Other firms have increased targets (Mizuho $250, BTIG $215, Chardan $210), signaling broad analyst conviction and adding buying pressure from funds tracking upgrades. Chardan Capital Boosts Palvella Therapeutics Price Target to $210.00
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise roughly $200M (plus a 30‑day option on 240k shares). The proceeds will fund QTORIN programs and R&D (cash runway positive), but the issuance dilutes current shareholders and adds near‑term supply. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest rose ~22% in February to about 1.67M shares (~17.8% of float) with ~5.5 days to cover; sizable short positions can pressure the stock if trial/clinical timelines slip, though they can also amplify rallies in the near term. Insider sales have also been reported, which some investors view negatively. (No single article link provided in the feed.)

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.